Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.



Zeenath Banu*, Azra Fatima, Sarwar Fatima, Syeda Fatimuz Zohra, Tabassum Sultana


Parkinson’s disease, first described by James Parkinson in 1817, is a neurodegenerative ailment resulting from the damage of nerve cells in the brain. It is a chronic, progressive, neurodegenerative disorder with an estimated prevalence of 31 to 328 per 100,000 people worldwide. It is estimated that more than 1 percent of the population over age 65 are afflicted with Parkinson’s disease; incidence and prevalence increase with age. There are numerous unanswered questions regarding the diagnosis and management of Parkinson’s disease. Worsening mobility, causing problems with activities of daily living, pain and communication problems due to rigidity of facial muscles, are the main reasons of their decreasing quality of life. This study is focused on the role of psychological variables, which could be associated with quality of life in PD patients. After their identification a discussion about opportunities of improvement patient’s quality of life can be opened. Current drug therapies for human PD with Levodopa or various dopamine receptor agonists offer symptomatic relief and appear to have little effect on the neurodegenerative process. More than 50% of patients with PD treated over 5 years with Levodopa will develop complications such as motor fluctuations and dyskinesia’s. In this scenario, slowing the progression of PD through neuroprotective or restorative therapy is a major focus of research. From a pharmacologic standpoint, current strategies involve interrupting the cascade of biochemical events that leads to death of dopaminergic cells. The significance of many indigenous medicinal plants and their phytoconstitutents in the management of Parkinsonism with minimal side effect profile arise in this context.

Keywords: Parkinson’s disease, Dopamine, Lewy bodies.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More